{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:41:53Z","timestamp":1793295713800,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The aim of this paper is to critically re-appraise the published trials assessing propranolol for migraine prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We report methods and results following the Preferred Reporting Items for Systematic Reviews (PRISMA), by searching MEDLINE, EMBASE, Cochrane CENTRAL, and ClinicalTrials.gov for randomized trials of pharmacologic treatments for migraine prophylaxis. We included randomized trials that compared propranolol with placebo for migraine prophylaxis in adults. The outcomes of interest were informed by the Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG) and include the proportion of patients who experience a 50% or more reduction in monthly migraine days, the reduction of monthly migraine days, and the number of adverse events leading to discontinuation. We assessed risk of bias by using a modified Cochrane RoB (risk of bias) 2.0 tool and the certainty of evidence by using the GRADE approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our search yielded twenty trials (<jats:italic>n<\/jats:italic>\u2009=\u20091291 patients) eligible for data synthesis and analysis. The analysis revealed a moderate certainty evidence that propranolol leads to a reduction in monthly migraine days versus placebo (-1.27; 95% CI: -2.25 to -0.3). We found moderate certainty evidence that propranolol increases the proportion of patients who experience a 50% or more reduction in monthly migraine days, compared to placebo with a relative risk of 1.65 (95% CI 1.41 to 1.93); absolute risk difference: 179 more per 1,000 (95% CI 113 to 256). We found high certainty evidence that propranolol increases the proportion of patients who discontinue due to adverse events compared to placebo with a risk difference of 0.02 (95% CI 0.00 to 0.03); absolute risk difference: 20 more per 1,000 (95% CI 0 to 30).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present meta-analysis shows that propranolol has a prophylactic role in migraine, with an overall acceptable tolerability profile. Combining these results with its long-standing use and its global availability at a low cost confirms its role as a first line agent in the prophylaxis of migraine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01826-y","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T23:01:58Z","timestamp":1721775718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention\u00a0- part 4: propranolol"],"prefix":"10.1186","volume":"25","author":[{"given":"Jan","family":"Versijpt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muizz","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Boucherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"3","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/0002-9149(66)90056-7","volume":"18","author":"R Rabkin","year":"1966","unstructured":"Rabkin R, Stables DP, Levin NW, Suzman MM (1966) The prophylactic value of propranolol in angina pectoris. Am J Cardiol 18(3):370\u2013383","journal-title":"Am J Cardiol"},{"issue":"5921","key":"1826_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/bmj.2.5921.699","volume":"2","author":"TE Wideroe","year":"1974","unstructured":"Wideroe TE, Vigander T (1974) Propranolol in the treatment of migraine. Br Med J 2(5921):699\u2013701","journal-title":"Br Med J"},{"issue":"7","key":"1826_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache S (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 61(7):1021\u201339","journal-title":"Headache."},{"issue":"1","key":"1826_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V et al (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 20(1):57","journal-title":"J Headache Pain"},{"issue":"9","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine\u2013revised report of an EFNS task force. Eur J Neurol 16(9):968\u2013981","journal-title":"Eur J Neurol"},{"issue":"2","key":"1826_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1161\/01.HYP.2.2.228","volume":"2","author":"K Takeda","year":"1980","unstructured":"Takeda K, Bunag RD (1980) Chronic propranolol treatment inhibits sympathetic nerve activity and keeps blood pressure from rising in spontaneously hypertensive rats. Hypertension 2(2):228\u2013235","journal-title":"Hypertension"},{"issue":"6","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0002-9343(76)90904-9","volume":"60","author":"P Lewis","year":"1976","unstructured":"Lewis P (1976) The essential action of propranolol in hypertension. Am J Med 60(6):837\u2013852","journal-title":"Am J Med"},{"key":"1826_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.podrm.2017.02.006","volume":"42","author":"AA Al-Majed","year":"2017","unstructured":"Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H (2017) Propranolol. Profiles Drug Subst Excip Relat Methodol 42:287\u2013338","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"9","key":"1826_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/acn3.51640","volume":"9","author":"E Rubio-Beltran","year":"2022","unstructured":"Rubio-Beltran E, Schoon RM, van den Berg J, Schuiling-Veninga CCM, Koch BCP, Villalon CM et al (2022) Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol 9(9):1405\u20131416","journal-title":"Ann Clin Transl Neurol"},{"issue":"Pt 1","key":"1826_CR10","first-page":"86","volume":"128","author":"KG Shields","year":"2005","unstructured":"Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128(Pt 1):86\u201397","journal-title":"Brain"},{"issue":"4","key":"1826_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59(4):652\u2013661","journal-title":"Ann Neurol"},{"issue":"3","key":"1826_CR12","doi-asserted-by":"publisher","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","volume":"14","author":"JL Jackson","year":"2019","unstructured":"Jackson JL, Kuriyama A, Kuwatsuka Y, Nickoloff S, Storch D, Jackson W et al (2019) Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 14(3):e0212785","journal-title":"PLoS One"},{"key":"1826_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104587","volume":"151","author":"C Fumagalli","year":"2020","unstructured":"Fumagalli C, Maurizi N, Marchionni N, Fornasari D (2020) beta-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res 151:104587","journal-title":"Pharmacol Res"},{"issue":"3","key":"1826_CR14","first-page":"427","volume":"43","author":"N Adham","year":"1993","unstructured":"Adham N, Ellerbrock B, Hartig P, Weinshank RL, Branchek T (1993) Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol 43(3):427\u2013433","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1826_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Garcia-Azorin D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R et al (2023) European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain 24(1):134","journal-title":"J Headache Pain"},{"issue":"1","key":"1826_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-023-01573-6","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, Versijpt J, Amin FM, Deligianni CI, Gil-Gouveia R, Jassal T et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain 24(1):39","journal-title":"J Headache Pain"},{"issue":"1","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","volume":"24","author":"CI Deligianni","year":"2023","unstructured":"Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gil-Gouveia R, MaassenVanDenBrink A et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain 24(1):128","journal-title":"J Headache Pain"},{"key":"1826_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"1826_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1749-6632.1993.tb26343.x","volume":"703","author":"K Dickersin","year":"1993","unstructured":"Dickersin K, Min YI (1993) Publication bias: the problem that won\u2019t go away. Ann N Y Acad Sci 703:135\u201346.\u00a0discussion 46\u20138","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1826_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043242","volume":"11","author":"K Haywood","year":"2021","unstructured":"Haywood K, Potter R, Froud R, Pearce G, Box B, Muldoon L et al (2021) Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open 11(11):e043242","journal-title":"BMJ Open"},{"key":"1826_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD et al (2020) Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 370:m2980","journal-title":"BMJ"},{"key":"1826_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"32","key":"1826_CR23","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA et al (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 192(32):E901\u2013E906","journal-title":"CMAJ"},{"issue":"4","key":"1826_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160","journal-title":"Evid Based Ment Health"},{"issue":"7650","key":"1826_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"1826_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","volume":"137","author":"L Zeng","year":"2021","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G et al (2021) GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 137:163\u2013175","journal-title":"J Clin Epidemiol"},{"key":"1826_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126\u2013135","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1826_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1468-2982.1993.1302128.x","volume":"13","author":"HK Al-Qassab","year":"1993","unstructured":"Al-Qassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia. 1993;13(2):128\u201331.","journal-title":"Cephalalgia."},{"issue":"1","key":"1826_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1526-4610.1976.hed1601024.x","volume":"16","author":"S Diamond","year":"1976","unstructured":"Diamond S, Medina JL (1976) Double blind study of propranolol for migraine prophylaxis. Headache 16(1):24\u201327","journal-title":"Headache"},{"issue":"6","key":"1826_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1468-2982.1996.1606441.x","volume":"16","author":"HC Diener","year":"1996","unstructured":"Diener HC, Foh M, Iaccarino C, Wessely P, Isler H, Strenge H et al (1996) Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group Cephalalgia 16(6):441\u2013447","journal-title":"Cephalalgia"},{"issue":"8","key":"1826_CR31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","volume":"251","author":"HC Diener","year":"2004","unstructured":"Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ et al (2004) Topiramate in migraine prophylaxis\u2013results from a placebo-controlled trial with propranolol as an active control. J Neurol 251(8):943\u2013950","journal-title":"J Neurol"},{"issue":"5","key":"1826_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1526-4610.1976.hed1605238.x","volume":"16","author":"B Forssman","year":"1976","unstructured":"Forssman B, Henriksson KG, Johannsson V, Lindvall L, Lundin H (1976) Propranolol for migraine prophylaxis. Headache 16(5):238\u2013245","journal-title":"Headache"},{"key":"1826_CR33","doi-asserted-by":"publisher","first-page":"c4871","DOI":"10.1136\/bmj.c4871","volume":"341","author":"KA Holroyd","year":"2010","unstructured":"Holroyd KA, Cottrell CK, O\u2019Donnell FJ, Cordingley GE, Drew JB, Carlson BW et al (2010) Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 341:c4871","journal-title":"BMJ"},{"issue":"4","key":"1826_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1526-4610.1973.hed1204163.x","volume":"12","author":"BP Malvea","year":"1973","unstructured":"Malvea BP, Gwon N, Graham JR (1973) Propranolol prophylaxis of migraine. Headache 12(4):163\u2013167","journal-title":"Headache"},{"issue":"4","key":"1826_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1600-0404.1986.tb03299.x","volume":"73","author":"B Mikkelsen","year":"1986","unstructured":"Mikkelsen B, Pedersen KK, Christiansen LV (1986) Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand 73(4):423\u2013427","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1826_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1526-4610.1986.hed2604175.x","volume":"26","author":"JW Nadelmann","year":"1986","unstructured":"Nadelmann JW, Phil M, Stevens J, Saper JR (1986) Propranolol in the prophylaxis of migraine. Headache 26(4):175\u2013182","journal-title":"Headache"},{"issue":"4","key":"1826_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1046\/j.1468-2982.1989.904247.x","volume":"9","author":"A Pradalier","year":"1989","unstructured":"Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M et al (1989) Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 9(4):247\u2013253","journal-title":"Cephalalgia"},{"issue":"6","key":"1826_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1526-4610.1985.hed2506320.x","volume":"25","author":"J Sargent","year":"1985","unstructured":"Sargent J, Solbach P, Damasio H, Baumel B, Corbett J, Eisner L et al (1985) A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 25(6):320\u2013324","journal-title":"Headache"},{"issue":"13","key":"1826_CR39","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT et al (2012) Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 78(13):976\u2013984","journal-title":"Neurology"},{"issue":"3","key":"1826_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1468-2982.1982.0203165.x","volume":"2","author":"B Standnes","year":"1982","unstructured":"Standnes B (1982) The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia 2(3):165\u2013170","journal-title":"Cephalalgia"},{"issue":"4","key":"1826_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1526-4610.1980.h2004006.x","volume":"20","author":"P Stensrud","year":"1980","unstructured":"Stensrud P, Sjaastad O (1980) Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 20(4):204\u2013207","journal-title":"Headache"},{"issue":"7","key":"1826_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","volume":"34","author":"LJ Stovner","year":"2014","unstructured":"Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T et al (2014) A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34(7):523\u2013532","journal-title":"Cephalalgia"},{"issue":"1","key":"1826_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0404.1984.tb07772.x","volume":"69","author":"P Tfelt-Hansen","year":"1984","unstructured":"Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J (1984) Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69(1):1\u20138","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1826_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.22.4.366","volume":"22","author":"RB Weber","year":"1972","unstructured":"Weber RB, Reinmuth OM (1972) The treatment of migraine with propranolol. Neurology 22(4):366\u2013369","journal-title":"Neurology"},{"issue":"8","key":"1826_CR45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/archneur.1993.00540080036010","volume":"50","author":"DK Ziegler","year":"1993","unstructured":"Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J (1993) Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects Arch Neurol 50(8):825\u2013830","journal-title":"Arch Neurol"},{"issue":"1","key":"1826_CR46","first-page":"65","volume":"4","author":"G Nappi","year":"1989","unstructured":"Nappi G, Agnoli A, Manzoni GC, Nattero G, Sicuteri F (1989) Classification and diagnostic criteria for primary headache disorders (Ad Hoc Committee IHS, 1988). Funct Neurol 4(1):65\u201371","journal-title":"Funct Neurol"},{"key":"1826_CR47","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"1826_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1600-0404.1986.tb04591.x","volume":"73","author":"RH Johnson","year":"1986","unstructured":"Johnson RH, Hornabrook RW, Lambie DG (1986) Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 73(5):490\u2013492","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1826_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain 24(1):56","journal-title":"J Headache Pain"},{"issue":"1","key":"1826_CR50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-023-01666-2","volume":"24","author":"P Martelletti","year":"2023","unstructured":"Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24(1):140","journal-title":"J Headache Pain"},{"issue":"1","key":"1826_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-023-01700-3","volume":"25","author":"M Leonardi","year":"2024","unstructured":"Leonardi M, Martelletti P, Burstein R, Fornari A, Grazzi L, Guekht A et al (2024) The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders. J Headache Pain 25(1):4","journal-title":"J Headache Pain"},{"issue":"4","key":"1826_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/14737167.2024.2321244","volume":"24","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Martelletti P (2024) A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health? Expert Rev Pharmacoecon Outcomes Res 24(4):459\u2013461","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"1826_CR53","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044","journal-title":"Cephalalgia"},{"key":"1826_CR54","doi-asserted-by":"crossref","unstructured":"Chowdhury D, Bansal L, Duggal A, Datta D, Mundra A, Krishnan A, et al (2021) TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42(4-5):396\u2013408.","DOI":"10.1177\/03331024211047454"},{"key":"1826_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1416","volume":"348","author":"TJ Schwedt","year":"2014","unstructured":"Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416","journal-title":"BMJ"},{"issue":"3","key":"1826_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.0306-5251.2001.01459.x","volume":"52","author":"V Limmroth","year":"2001","unstructured":"Limmroth V, Michel MC (2001) The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 52(3):237\u2013243","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1826_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1526-4610.1978.hed1801020.x","volume":"18","author":"RN Nanda","year":"1978","unstructured":"Nanda RN, Johnson RH, Gray J, Keogh HJ, Melville ID (1978) A double blind trial of acebutolol for migraine prophylaxis. Headache 18(1):20\u201322","journal-title":"Headache"},{"issue":"1","key":"1826_CR58","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128","journal-title":"J Headache Pain"},{"issue":"6","key":"1826_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488","journal-title":"Cephalalgia"},{"issue":"3","key":"1826_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","volume":"144","author":"JG Baker","year":"2005","unstructured":"Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144(3):317\u2013322","journal-title":"Br J Pharmacol"},{"key":"1826_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00033","volume":"13","author":"C Laurens","year":"2019","unstructured":"Laurens C, Abot A, Delarue A, Knauf C (2019) Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier. Front Neurosci 13:33","journal-title":"Front Neurosci"},{"issue":"1","key":"1826_CR62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1526-4610.2007.00785.x","volume":"48","author":"R Schellenberg","year":"2008","unstructured":"Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K (2008) Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache 48(1):118\u2013125","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01826-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T23:02:18Z","timestamp":1721775738000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01826-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"9 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FA reports personal fees for lecturing and\/or participating in advisory board for AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva. RGG reports honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lily, Lundbeck, Novartis, Teva, Organon, Pfizer; participated in clinical trials as the principal investigator for Amgen, Novartis and Lundbeck; received research grants from Novartis. CD has received IHS research fellowship grant and Hellenic Society of Neurology scholarship. AMvdB received honoraria, research and\/or travel grants from Allergan\/Abbvie, Amgen\/Novartis, Eli Lilly, Satsuma and Teva as principal investigator. JV received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan\/AbbVie. SS reports personal fees as speaker or advisor for Abbott, Allergan-Abbvie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva; research grants from Novartis and Uriach; fees for CME\/education from Medscape and Neurodiem Ology Medical Education; Intellectual as president elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, assistant editor for Stroke. CL has received consulting fees and honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lily, Lundbeck, Novartis and Teva. CL participated in clinical trials as the principal investigator for Eli Lilly. Intellectual as president of the European Headache Federation, associate editor for The Journal of Headache and Pain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}